Your browser doesn't support javascript.
loading
Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site.
Stadlbauer, Daniel; McMahon, Meagan; Turner, Hannah L; Zhu, Xueyong; Wan, Hongquan; Carreño, Juan Manuel; O'Dell, George; Strohmeier, Shirin; Khalil, Zain; Luksza, Marta; van Bakel, Harm; Simon, Viviana; Ellebedy, Ali H; Wilson, Ian A; Ward, Andrew B; Krammer, Florian.
Afiliação
  • Stadlbauer D; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • McMahon M; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Turner HL; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
  • Zhu X; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
  • Wan H; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
  • Carreño JM; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • O'Dell G; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Strohmeier S; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Khalil Z; Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria.
  • Luksza M; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • van Bakel H; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Simon V; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Ellebedy AH; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Wilson IA; Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Ward AB; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Krammer F; Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nat Commun ; 13(1): 7864, 2022 12 21.
Article em En | MEDLINE | ID: mdl-36543789
Contemporary influenza A H3N2 viruses circulating since 2016 have acquired a glycosylation site in the neuraminidase in close proximity to the enzymatic active site. Here, we investigate if this S245N glycosylation site, as a result of antigenic evolution, can impact binding and function of human monoclonal antibodies that target the conserved active site. While we find that a reduction in the inhibitory ability of neuraminidase active site binders is measurable, this class of broadly reactive monoclonal antibodies maintains protective efficacy in vivo.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírus da Influenza A Subtipo H3N2 / Anticorpos Monoclonais / Neuraminidase Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírus da Influenza A Subtipo H3N2 / Anticorpos Monoclonais / Neuraminidase Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article